ClinicalTrials.gg
RecruitingNCT07783971Updated Aug 25, 2026

Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics and Its Clinical Relevance

An observational study in Fungal Diseases, Lung Cancer (NSCLC) and Microbioata, sponsored by 958th Army Hospital of the Chinese People's Liberation Army. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by 958th Army Hospital of the Chinese People's Liberation Army · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
10
Ages
30 Years to 80 Years
Sex
All
01

Study summary

This study aims to uncover the characteristics of the fungal flora in non-small cell lung cancer, and to investigate the relationship between pulmonary fungi and the various pathological subtypes, stages, clinical features of non-small cell lung cancer, as well as patient prognosis. It seeks to provide new perspectives for a comprehensive understanding of non-small cell lung cancer, as well as new approaches for its early diagnosis and prognosis assessment.

Read the detailed description

This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.

This project intends to study the structural characteristics and clinical relevance of fungal microbiota in lung tissue of patients with non-small cell lung cancer. The project plans to collect 500 lung tissue samples from patients undergoing lung cancer surgery, build an ecological map of non-small cell lung cancer fungi through high-throughput sequencing, and simultaneously carry out traditional fungi culture to obtain culturable strain resources, so as to build a resource bank of non-small cell lung cancer fungi. By integrating clinicopathological information and follow-up data, using bioinformatics and statistical methods, key landmark fungi were screened, and the correlation between fungal community structure and different pathological subtypes, stages and clinical characteristics of non-small cell lung cancer was analyzed.

02

Conditions studied

  • Fungal Diseases
  • Lung Cancer (NSCLC)
  • Microbioata

Keywords

  • the lung microbiome
03

In context

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

This study's planned enrollment of 10 is below the median of 153 across 85 observational studies indexed under Mycoses.

Browse Mycoses studies →

Lead sponsor

This is the only study on the registry with 958th Army Hospital of the Chinese People's Liberation Army as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The research object is the patients who are newly diagnosed as "non-small cell lung cancer" and intend to undergo surgical resection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Non-small cell lung cancer was diagnosed by before operation, frozen pathology during operation or paraffin section after operation; The patients were 30 to 80 years old; No chemotherapy, radiotherapy, targeted therapy or immunotherapy were given before operation;

Exclusion criteria

Exclusion Criteria:

Patients who do not meet the inclusion criteria; Combined with primary malignant tumor of other systems or recurrence of lung cancer, combined with immunodeficiency disease; Acute exacerbation of , bronchial asthma, bronchiectasis with infection, tuberculosis and pneumoconiosis; recent use of antifungal drugs; Basic clinical information (such as pathological type, clinical stage and treatment plan) cannot be obtained;

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Lung cancer group

    The samples included in this group were lung cancer tissues.

  • Normal lung tissue group

    The samples included in this group were normal lung tissues.

06

What researchers measure

Primary outcomes

  1. the fungal microbial environment

    Different fungal microbial environments were observed in different parts of lung tissue.

    Time frame: baseline, pre-surgery

07

Study locations

1 of 1 sites recruiting
  • 958th Army Hospital
    Chongqing, Liangjiang New 400020, China
    Recruiting
08

References and documents

Publications

  • Dohlman AB, Klug J, Mesko M, Gao IH, Lipkin SM, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell. 2022 Sep 29;185(20):3807-3822.e12. doi: 10.1016/j.cell.2022.09.015. PubMed 36179671 ↗
  • Liu NN, Yi CX, Wei LQ, Zhou JA, Jiang T, Hu CC, Wang L, Wang YY, Zou Y, Zhao YK, Zhang LL, Nie YT, Zhu YJ, Yi XY, Zeng LB, Li JQ, Huang XT, Ji HB, Kozlakidis Z, Zhong L, Heeschen C, Zheng XQ, Chen C, Zhang P, Wang H. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell. 2023 Nov 13;41(11):1927-1944.e9. doi: 10.1016/j.ccell.2023.08.012. Epub 2023 Sep 21. PubMed 37738973 ↗
  • Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, Gonzalez A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 Sep 29;185(20):3789-3806.e17. doi: 10.1016/j.cell.2022.09.005. PubMed 36179670 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2026
First posted
Aug 25, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Jan 30, 2028
CompletionEst.
Aug 1, 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07783971
Lead sponsor
958th Army Hospital of the Chinese People's Liberation Army
Responsible party
youlinghou (resident physician, 958th Army Hospital of the Chinese People's Liberation Army) — Principal investigator
First posted
Aug 25, 2026
Start date
Aug 1, 2026
Primary completion
Jan 30, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

shunhong wang project leader
Contact
wangshunhong918@163.com
023-68762084

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion